OPTOA
Asset Logo

Opthea Limited

πŸ‡¦πŸ‡Ί ASX

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

1
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Opthea Limited - Option Expiring 31-Aug-2025

πŸ“ˆ Performance

Price History

N/A

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.41

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in OPTOA

1

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

9 weeks

πŸ’΅ Average investment amount

$3,644

⏰ Last time a customer invested in OPTOA

196 days
OPTOA investor breakdown
πŸ’΅ Income of investors

More than 200k

50%

150k - 200k

100k - 150k

50k - 100k

Less than 50k

50%
πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

100%
πŸ™‹ Legal gender of investors

Female

Male

100%

Pearlers who invest in OPTOA also invest in...

BetaShares Asia Technology Tigers ETF

ASIA

ASIA.AX was created on 2018-09-18 by BetaShares. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the BetaShares Asia Technology Tigers ETF is to provide an investment return that aims to track the performance of the Solactive Asia ex-Japan Technology & Internet Tigers Index (the Index), before taking into account fees and expenses.

πŸ™Œ Performance (5Yr p.a)

8.17%

πŸ“Š Share price

$9.62 AUD

πŸ“ˆ HIGH PRICE GROWTH

Find Out More

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

13.23%

πŸ“Š Share price

$134.96 AUD

🌏 GLOBAL

πŸ€– TECHNOLOGY

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

πŸ™Œ Performance (5Yr p.a)

25.73%

πŸ“Š Share price

$47.45 AUD

πŸ€– TECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

πŸ™Œ Performance (5Yr p.a)

-15.75%

πŸ“Š Share price

$0.60 AUD

🧬 BIOTECHNOLOGY

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

4.35%

πŸ“Š Share price

$104.33 AUD

⛳️ DIVERSIFIED

🧱 MATERIALS

πŸ’Έ FINANCIALS

Want more shares? Try these...

πŸ“Š Share price

$0.28 AUD

Orora Ltd. engages in the manufacturing and distribution of fiber, glass and aluminum beverage cans. The company is headquartered in Hawthorn, Victoria and currently employs 4,657 full-time employees. The company went IPO on 2013-12-18. The company supplies packaging products and services to the grocery, fast moving consumer goods and industrial markets. The Company’s Australasia segment focuses on the manufacture of beverage packaging products within Australia and New Zealand. Its North America segment is predominately located in North America, which purchases, warehouses, sells and delivers a range of packaging and other related materials. The business also includes integrated corrugated sheet and box manufacturing and equipment sales capabilities and point of purchase retail display solutions and other visual communication services. Its Saverglass business is engaged in the design, manufacturing, customization and decoration of high-end bottles and provides for the premium and super-premium spirits, fine wine and champagne markets.

πŸ™Œ Performance (5Yr p.a)

-7.52%

πŸ“Š Share price

$2.52 AUD

πŸ’° HIGH DIVIDEND

πŸ“¦ LOGISTICS

πŸ•ŠοΈ SOCIALLY AWARE

πŸ“Š Share price

$0.00 AUD

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

πŸ™Œ Performance (5Yr p.a)

-15.75%

πŸ“Š Share price

$0.60 AUD

🧬 BIOTECHNOLOGY

Compare
Add to watchlist